Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New math models could save lives on liver transplant waitlist

NCT ID NCT03820271

Knowledge-focused Sponsor: Assistance Publique - Hôpitaux de Paris Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study aimed to create new mathematical models to better predict which patients with severe liver disease are at highest risk of dying while waiting for a liver transplant. Researchers analyzed data from 501 adults on the French national transplant waiting list. The goal is to make the organ allocation system fairer and reduce deaths on the waiting list.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

501 people

The number who actually took part.

Started

Oct 2020

Finished

Nov 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adult patients (≥18 years old) registered on national waiting list with main diagnosis "cirrhosis" within 14 days (+/-2) before or 7 days (+/-2) after the inclusion in the protocol (using the date of biobank sampling as Day 0) * Patients enrolled on the national waiting list under the "national liver score" allocation scheme whether an expert component is considered or not * Patients (or trusted person or family member or close relation if the patient is unable to express consent) who have been informed and signed their informed consent * Patients affiliated to a health insurance scheme Exclusion Criteria: * Patients enrolled with decompensated cirrhosis associated with hepatocellular carcinoma \>TNM1 * Patients on AVK (INR and therefore MELD and CLIF scores uninterpretable) * Vulnerable population (person under guardianship or curatorship or deprived of liberty by a judicial decision) * Pregnant and / or breastfeeding woman * Patient candidate for a combined transplantation * Patient with history of organ transplantation (liver, kidney, heart)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Decompensated cirrhosis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

chronic liver failure cirrhosis of liver

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Decompensated cirrhosis Liver transplantation

Contacts and locations

Locations

  • Pr Duvoux

    Créteil, 94000, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.